Power Law company profile

ChemoCentryx

Biotech & Life Sciences · San Carlos, United States · Founded 1997 · IPO 2012 Unicorn

Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants

Valuation

$569M

Market cap · May/2026

Revenue

$90M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

7 investors on ChemoCentryx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage

Jennison Associates

OrbiMed

HealthCap

Alta Partners

Gimv

Bio-Techne

HBM Healthcare Investments

Global footprint

Where ChemoCentryx has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States96.3%

🇮🇳 India3.8%

2 countries shown

Patent intelligence

$524M patent portfolio · 156 active families

Estimated portfolio value

$524M

92.1% of market cap · 2.3× the top peer Ganymed Pharmaceuticals ($223M)

156 active patent families

Where ChemoCentryx innovates DiseaseAntagonistMolecular biologyArylPharmaceutical Substances

Where ChemoCentryx concentrates vs peers

Each axis is a top-10 topic across ChemoCentryx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about ChemoCentryx

An AI-synthesized read of the highest-engagement posts about ChemoCentryx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ChemoCentryx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles